Human stanniocalcin and uses thereof to inhibit adipogenesis
CA 2325390 A1 · Owner: Yamaguchi, Kyoji · Inventors: Kobayashi, Fumie; Mochizuki, Shin-Ichi; Tomoyasu, Akihiro
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel protein which is a glycoprotein having activities of suppressing the differentiation and/or maturation of adipocytes having a molecular weight of , about 45 kDa under nonreducing conditions and about 28 kDa and/or about 23 kDa under reducing conditions, and having an affinity for heparin. A process for producing the above protein which comprises culturing human fibroblasts and purifying the product from the liquid culture medium by ion exchange column affinity column and reversed phase column chromatographs. A cDNA encoding the above protein and a process for producing the above protein by using this cDNA. This protein is useful in medicinal compositions aiming at preventing …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 9, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 9, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 9, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.